BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, March 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2002

View Archived Issues

Novel COX-2 inhibitors in early development at GSK

Read More

Tachykinin antagonists for use in depression and other disorders

Read More

Synthesis of novel 5-HT2A receptor ligands reported at Medicinal Chemistry Symposium

Read More

Abbott identifies aryl tetrahydropyridine farnesyltransferase inhibitors

Read More

Biological activity of paclitaxel-glucose conjugate tested in human cancer cell lines

Read More

Discovery of CCR3 receptor antagonists with potential in allergic asthma

Read More

Novel antiinflammatory agents from Celgene act by inhibiting transcriptional activation in T-cells

Read More

A wealth of data on lumiracoxib presented at the EULAR congress

Read More

NN-2211 may be useful for treating obesity and type 2 diabetes

Read More

Preclinical findings reported for aldose reductase inhibitor fidarestat

Read More

New data on ragaglitazar discussed at the ADA scientific sessions

Read More

Lead PTP1B inhibitor with blood glucose-lowering effects identified by Korean group

Read More

Hydroxamate-based antibiotics targeting LpxC in Gram-negative bacteria

Read More

DISC-GMCSF completes phase I study

Read More

NDA filing for Purdue's abuse-resistant pain medication delayed

Read More

FSME-IMMUN vaccine approved for adult use in Germany

Read More

Chiron grants nonexclusive HCV license to Merck & Co.

Read More

Argenta Discovery and Amedis enter drug discovery collaboration

Read More

Immtech's lead hepatitis C compounds to be validated for further development

Read More

Trospium completes phase III trial in overactive bladder

Read More

CoFactor phase II trial design finalized

Read More

Asthma drug candidate selected under Texas Biotechnology/Schering-Plough collaboration

Read More

Frova launched in U.S.

Read More

Human 5-HT2C receptor ligands selected for further evaluation at Vernalis for use in obesity

Read More

Sankyo patents new antitumor compounds

Read More

3-Dimensional presents new trypsin-like protease inhibitors in recent patent

Read More

Potent inhibitors of IL-12 production and potential therapeutic applications

Read More

Mast cell stabilizers synthesized at Alcon active in model of allergic conjunctivitis

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 13, 2026.
  • Art concept for targeting the brain

    Precision psychiatry beyond, or before, biomarkers

    BioWorld
    There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 10, 2026
  • Illustration of a motor neuron

    Keros reports beneficial effects of RKER-065 in ALS model

    BioWorld Science
    Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
  • Skin irritation on hands

    HX-16108 holds promise for treating inflammatory skin diseases

    BioWorld Science
    Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing